{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:05Z","timestamp":1792047125680,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00832-9","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:11:01Z","timestamp":1760101861000},"page":"2295-2312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["SGLT-2 Inhibitors in the Prevention and Progression of Neurodegenerative Diseases: A Narrative Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Paulina","family":"Kostrzewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-5554","authenticated-orcid":false,"given":"Pawe\u0142","family":"Kuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Madetko Alster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Alster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"4","key":"832_CR1","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","volume":"13","author":"W Chen","year":"2016","unstructured":"Chen W, Zhang X, Huang W. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep. 2016;13(4):3391\u20136.","journal-title":"Mol Med Rep"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"1246979","DOI":"10.3389\/fendo.2023.1246979","volume":"14","author":"W Xu","year":"2024","unstructured":"Xu W, Wang X, Hou X, Yang Y, Ma R, Lv R, et al. The role of microglia in the pathogenesis of diabetic-associated cognitive dysfunction. Front Endocrinol. 2024;14:1246979.","journal-title":"Front Endocrinol"},{"key":"832_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2020.00001","volume":"12","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases. Front Aging Neurosci. 2020;12:1\u201310.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"832_CR4","first-page":"195","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Lee G, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2018. Alzh Dement: Trans Res Clin Interv. 2018;4(1):195\u2013214.","journal-title":"Alzh Dement: Trans Res Clin Interv"},{"issue":"10","key":"832_CR5","first-page":"3534","volume":"126","author":"J Janson","year":"2016","unstructured":"Janson J, Butler PC. Islet amyloid, insulin resistance, and type 2 diabetes. J Clin Invest. 2016;126(10):3534\u201343.","journal-title":"J Clin Invest"},{"issue":"9","key":"832_CR6","first-page":"754","volume":"41","author":"MF Egan","year":"2020","unstructured":"Egan MF, Kostka P. Neuroinflammation in Alzheimer\u2019s disease: mechanisms, implications, and therapeutic targets. Trends Pharmacol Sci. 2020;41(9):754\u201364.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"832_CR7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrg3373","volume":"14","author":"VH Perry","year":"2013","unstructured":"Perry VH, Teeling JL. Microglia and macrophages of the brain: function and dysfunction. Nat Rev Neurosci. 2013;14(2):125\u201337.","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"832_CR8","first-page":"1507","volume":"60","author":"G Pugliese","year":"2017","unstructured":"Pugliese G, Cossu F. Inflammation in diabetes and neurodegeneration: a connection. Diabetologia. 2017;60(8):1507\u201319.","journal-title":"Diabetologia"},{"issue":"1","key":"832_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-2005-7107","volume":"7","author":"E Steen","year":"2005","unstructured":"Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease \u2013 is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63\u201380.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"832_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.bbadis.2013.10.015","volume":"1842","author":"X Wang","year":"2014","unstructured":"Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer\u2019s disease. Biochim Biophys Acta. 2014;1842(8):1240\u20137.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"832_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nri3705","volume":"14","author":"MT Heneka","year":"2014","unstructured":"Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463\u201377. https:\/\/doi.org\/10.1038\/nri3705.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"832_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","volume":"46","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957\u201367. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.006.","journal-title":"Immunity"},{"issue":"28","key":"832_CR13","doi-asserted-by":"publisher","first-page":"9090","DOI":"10.1523\/JNEUROSCI.1357-09.2009","volume":"29","author":"X Wang","year":"2009","unstructured":"Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer\u2019s disease. J Neurosci. 2009;29(28):9090\u2013103. https:\/\/doi.org\/10.1523\/JNEUROSCI.1357-09.2009.","journal-title":"J Neurosci"},{"issue":"1","key":"832_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-009-0521-3","volume":"118","author":"R Sultana","year":"2009","unstructured":"Sultana R, Perluigi M, Butterfield DA. Oxidatively modified proteins in Alzheimer\u2019s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009;118(1):131\u201350. https:\/\/doi.org\/10.1007\/s00401-009-0521-3.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"832_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res. 2015;12(2):78\u201389.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"22","key":"832_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"832_CR17","first-page":"891","volume":"143","author":"N Sattar","year":"2021","unstructured":"Sattar N, McGuire DK. Pathways to cardiorenal benefits with SGLT2 inhibition: evidence for multiple mechanisms. Circulation. 2021;143(10):891\u20134.","journal-title":"Circulation"},{"issue":"4","key":"832_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41581-022-00656-y","volume":"19","author":"WL Lau","year":"2023","unstructured":"Lau WL, Fisher M. New insights into cognitive decline in chronic kidney disease. Nat Rev Nephrol. 2023;19(4):214\u20135.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"832_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","volume":"13","author":"Z Wang","year":"2024","unstructured":"Wang Z, et al. SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system. Transl Neurodegener. 2024;13(1):41. https:\/\/doi.org\/10.1186\/s40035-024-00431-y.","journal-title":"Transl Neurodegener"},{"key":"832_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev-pharmtox-052120-014725","volume":"62","author":"KS Shah","year":"2022","unstructured":"Shah KS, Fang JC. Sodium-glucose cotransporter 2 inhibitors in heart failure. Annu Rev Pharmacol Toxicol. 2022;62:109\u201320.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"832_CR21","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.3390\/ijms22115863","volume":"22","author":"SN Munshi","year":"2021","unstructured":"Munshi SN, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22(11):5863.","journal-title":"Int J Mol Sci"},{"key":"832_CR22","first-page":"100933","volume":"36","author":"A Poudel","year":"2021","unstructured":"Poudel A, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations: meta-analysis. EClin Med. 2021;36:100933.","journal-title":"EClin Med"},{"key":"832_CR23","doi-asserted-by":"publisher","first-page":"668614","DOI":"10.3389\/fnagi.2021.668614","volume":"13","author":"A Dunalska","year":"2021","unstructured":"Dunalska A, Pikul J, Schok K, Wiejak KA, Alster P. The significance of vascular pathogenesis in the examination of corticobasal syndrome. Front Aging Neurosci. 2021;13:668614.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"832_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/jnnp-2020-324144","volume":"92","author":"I Sibon","year":"2021","unstructured":"Sibon I, et al. Environmental risk factors for progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2021;92(5):541\u20137. https:\/\/doi.org\/10.1136\/jnnp-2020-324144.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"832_CR25","unstructured":"Ghogare SN, Atallah R, Zelniker TA et al. SGLT2 inhibitors in cardiovascular medicine: pleiotropic effects. Eur Heart J Cardiovasc Pharmacother. 2022."},{"key":"832_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104870","volume":"158","author":"MS Usman","year":"2020","unstructured":"Usman MS, et al. Sotagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. 2020;158:104870.","journal-title":"Pharmacol Res"},{"key":"832_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.120964","volume":"321","author":"A Abduljawad","year":"2023","unstructured":"Abduljawad A, Abu-Elfotuh K, El-Azab MF, El-Naggar ME, El-Khatib AS. Ertugliflozin attenuates tau hyperphosphorylation, neuroinflammation, and mitochondrial dysfunction in a rat model of sporadic Alzheimer\u2019s disease. Life Sci. 2023;321:120964. https:\/\/doi.org\/10.1016\/j.lfs.2023.120964.","journal-title":"Life Sci"},{"key":"832_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112961","volume":"150","author":"AM Mohamed","year":"2022","unstructured":"Mohamed AM, El-Sayed WM. Dapagliflozin exerts neuroprotective effects against Alzheimer\u2019s disease in rats by targeting A\u03b2 burden, tau pathology, and neuroinflammation. Biomed Pharmacother. 2022;150:112961. https:\/\/doi.org\/10.1016\/j.biopha.2022.112961.","journal-title":"Biomed Pharmacother"},{"key":"832_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.136483","volume":"807","author":"Z Wang","year":"2023","unstructured":"Wang Z, Sun X, Zhang W, et al. SGLT2 inhibitors suppress NLRP3 inflammasome activation and neuroinflammation in Alzheimer\u2019s disease models. Neurosci Lett. 2023;807:136483. https:\/\/doi.org\/10.1016\/j.neulet.2023.136483.","journal-title":"Neurosci Lett"},{"key":"832_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106394","volume":"189","author":"J Ortiz-Abalia","year":"2024","unstructured":"Ortiz-Abalia J, Rodriguez-Perez AI, Garrido-Gil P, et al. Empagliflozin protects dopaminergic neurons and restores mitochondrial function in MPTP-induced Parkinson\u2019s disease mice model. Neurobiol Dis. 2024;189:106394. https:\/\/doi.org\/10.1016\/j.nbd.2024.106394.","journal-title":"Neurobiol Dis"},{"key":"832_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.lfs.2018.11.008","volume":"213","author":"A Mansour","year":"2018","unstructured":"Mansour A, Zaki HF, El Sayed MI, Kenawy SA. Empagliflozin alleviates cognitive impairment in diabetic rats: targeting brain insulin resistance, oxidative stress and inflammation. Life Sci. 2018;213:235\u201349. https:\/\/doi.org\/10.1016\/j.lfs.2018.11.008.","journal-title":"Life Sci"},{"key":"832_CR32","volume":"12","author":"T Matsuzaki","year":"2020","unstructured":"Matsuzaki T, Uchida S. The role of diabetes in neurodegenerative diseases: current perspectives and future directions. Front Aging Neurosci. 2020;12:171.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"832_CR33","first-page":"299","volume":"10","author":"MI Browning","year":"2020","unstructured":"Browning MI, Harriott AM. Vascular contributions to neurodegenerative disease. Neurodegener Dis Manag. 2020;10(5):299\u2013312.","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"832_CR34","first-page":"14","volume":"28","author":"MA Beydoun","year":"2014","unstructured":"Beydoun MA, Beydoun HA. Diabetes mellitus and its association with neurodegenerative diseases: a systematic review and meta-analysis. J Diabetes Complications. 2014;28(1):14\u201323.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"832_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","volume":"19","author":"VL Feigin","year":"2020","unstructured":"Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255\u201365.","journal-title":"Lancet Neurol"},{"issue":"1","key":"832_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40265-016-0674-0","volume":"77","author":"SM de la Monte","year":"2017","unstructured":"de la Monte SM. Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer\u2019s disease. Drugs. 2017;77(1):47\u201365.","journal-title":"Drugs"},{"issue":"3","key":"832_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","volume":"14","author":"SE Arnold","year":"2018","unstructured":"Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14(3):168\u201381.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"832_CR38","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: A \u201cThrifty Substrate\u201d Hypothesis. Diabetes Care. 2016;39(7):1108\u201314.","journal-title":"Diabetes Care"},{"issue":"1","key":"832_CR39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12974-021-02309-6","volume":"18","author":"DM Lee","year":"2021","unstructured":"Lee DM, Battson ML, Jarrell DK, et al. SGLT2 inhibition via dapagliflozin reduces neuroinflammation and improves cognitive function in obese mice. J Neuroinflammation. 2021;18(1):258.","journal-title":"J Neuroinflammation"},{"key":"832_CR40","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Xu L, Tian X, et al. SGLT2 inhibition improves brain insulin signaling and reduces neuroinflammation in diabetic mice. Front Pharmacol. 2022;13:848295.","journal-title":"Front Pharmacol"},{"issue":"1","key":"832_CR41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1530\/JOE-16-0631","volume":"234","author":"P Sa-Nguanmoo","year":"2017","unstructured":"Sa-Nguanmoo P, Kulthinee S, Pintana H, et al. Dapagliflozin improves cognitive function in streptozotocin-induced diabetic rats. J Endocrinol. 2017;234(1):41\u201350.","journal-title":"J Endocrinol"},{"key":"832_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136383","volume":"769","author":"B Lin","year":"2022","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Ishikawa Y. Luseogliflozin improves blood\u2013brain barrier integrity and reduces neuroinflammation in diabetic rats. Neurosci Lett. 2022;769:136383. https:\/\/doi.org\/10.1016\/j.neulet.2021.136383.","journal-title":"Neurosci Lett"},{"key":"832_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.941729","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ma Y, Ding L, Zhang L, Zhang Q, Wang S. Empagliflozin attenuates blood\u2013brain barrier dysfunction and neuroinflammation in a model of Alzheimer\u2019s disease with type 2 diabetes mellitus. Front Pharmacol. 2022;13:941729. https:\/\/doi.org\/10.3389\/fphar.2022.941729.","journal-title":"Front Pharmacol"},{"issue":"7","key":"832_CR44","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1523\/JNEUROSCI.4200-13.2014","volume":"34","author":"JR Erion","year":"2014","unstructured":"Erion JR, Wosiski-Kuhn M, Dey A, et al. Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity. J Neurosci. 2014;34(7):2618\u201331.","journal-title":"J Neurosci"},{"issue":"3","key":"832_CR45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JAD-200036","volume":"75","author":"K Kavanagh","year":"2020","unstructured":"Kavanagh K, Flynn DM, Feeman CA, et al. Neuroprotective effects of empagliflozin in a mouse model of Alzheimer\u2019s disease. J Alzheimers Dis. 2020;75(3):937\u201350.","journal-title":"J Alzheimers Dis"},{"key":"832_CR46","volume":"771","author":"IC Hwang","year":"2022","unstructured":"Hwang IC, Park SM, Lee HJ, et al. Dapagliflozin reduces amyloid-beta burden and neuroinflammation in a transgenic mouse model of Alzheimer\u2019s disease. Neurosci Lett. 2022;771:136414.","journal-title":"Neurosci Lett"},{"key":"832_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.760715","volume":"12","author":"Y Kim","year":"2021","unstructured":"Kim Y, Lee Y, Cho SJ, Jung I, Cho J. Empagliflozin ameliorates cognitive dysfunction and neuroinflammation in a mouse model of high-fat diet-induced obesity. Front Pharmacol. 2021;12:760715. https:\/\/doi.org\/10.3389\/fphar.2021.760715.","journal-title":"Front Pharmacol"},{"issue":"4","key":"832_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405. https:\/\/doi.org\/10.1016\/S1474-4422(15)70016-5.","journal-title":"Lancet Neurol"},{"issue":"6","key":"832_CR49","first-page":"317","volume":"27","author":"GG Kovacs","year":"2008","unstructured":"Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol. 2008;27(6):317\u201328 (PMID: 19065220).","journal-title":"Clin Neuropathol"},{"issue":"7","key":"832_CR50","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/NEN.0b013e31817d7e31","volume":"67","author":"Z Ahmed","year":"2008","unstructured":"Ahmed Z, Josephs KA, Gonzalez J, DelleDonne A, Dickson DW. Clinical and neuropathologic features of progressive supranuclear palsy with severe neocortical degeneration. J Neuropathol Exp Neurol. 2008;67(7):664\u201370. https:\/\/doi.org\/10.1097\/NEN.0b013e31817d7e31.","journal-title":"J Neuropathol Exp Neurol"},{"key":"832_CR51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1758-5996-6-36","volume":"6","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the SGLT2 inhibitor ipragliflozin preserves renal function and reduces inflammation in a mouse model of type 2 diabetes. Diabetol Metab Syndr. 2014;6:36.","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"832_CR52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/EJE-22-0113","volume":"187","author":"IK Wium-Andersen","year":"2022","unstructured":"Wium-Andersen IK, Wium-Andersen MK, J\u00f8rgensen MB, Osler M. Sodium-glucose cotransporter 2 inhibitors and risk of dementia: a population-based cohort study. Eur J Endocrinol. 2022;187(4):453\u201362. https:\/\/doi.org\/10.1530\/EJE-22-0113.","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"832_CR53","doi-asserted-by":"publisher","first-page":"S190","DOI":"10.2337\/dci22-0015","volume":"45","author":"A Cahn","year":"2022","unstructured":"Cahn A, Cefalu WT. Clinical considerations for use of SGLT2 inhibitors in type 2 diabetes. Diabetes Care. 2022;45(Suppl 1):S190\u20138. https:\/\/doi.org\/10.2337\/dci22-0015.","journal-title":"Diabetes Care"},{"issue":"2","key":"832_CR54","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.3390\/ijms24023024","volume":"24","author":"M Iwai","year":"2023","unstructured":"Iwai M, Fujita T. SGLT2 inhibitors and brain metabolism: therapeutic potential for neurodegeneration. Int J Mol Sci. 2023;24(2):3024. https:\/\/doi.org\/10.3390\/ijms24023024.","journal-title":"Int J Mol Sci"},{"key":"832_CR55","volume":"1751","author":"R Mohamed","year":"2021","unstructured":"Mohamed R, Said RS, El-Demerdash E. Mechanistic insights into the neuroprotective role of SGLT2 inhibitors in Alzheimer\u2019s disease: impact on oxidative stress and BDNF signaling. Brain Res. 2021;1751:147205.","journal-title":"Brain Res"},{"issue":"5","key":"832_CR56","first-page":"2811","volume":"43","author":"A Alhowail","year":"2022","unstructured":"Alhowail A, Almogbel Y, Almutairi B, et al. Neuroprotective effects of dapagliflozin in rotenone-induced Parkinson\u2019s disease model. Neurol Sci. 2022;43(5):2811\u20139.","journal-title":"Neurol Sci"},{"issue":"2","key":"832_CR57","first-page":"676","volume":"19","author":"IK Wium-Andersen","year":"2023","unstructured":"Wium-Andersen IK, Osler M, J\u00f8rgensen MB, et al. SGLT2 inhibitors and risk of dementia: a Danish nationwide cohort study. Alzheimers Dement. 2023;19(2):676\u201386.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"832_CR58","first-page":"e1253","volume":"107","author":"Z Yuan","year":"2022","unstructured":"Yuan Z, Zhang H, Liu W, et al. Comparative effectiveness of SGLT2 inhibitors on the risk of dementia in type 2 diabetes patients: a real-world data analysis. J Clin Endocrinol Metab. 2022;107(3):e1253\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"832_CR59","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"8","key":"832_CR60","first-page":"1915","volume":"44","author":"YS Lin","year":"2021","unstructured":"Lin YS, Chen YT, Hung SC, et al. Comparative risk of dementia in patients treated with GLP-1 receptor agonists vs SGLT2 inhibitors in Taiwan. Diabetes Care. 2021;44(8):1915\u201323.","journal-title":"Diabetes Care"},{"issue":"5","key":"832_CR61","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.numecd.2021.02.006.PubMed","volume":"31","author":"M Guo","year":"2021","unstructured":"Guo M, Ding J, Li J, et al. Effects of sodium-glucose cotransporter 2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(5):1365\u201374. https:\/\/doi.org\/10.1016\/j.numecd.2021.02.006.PubMed.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"832_CR62","doi-asserted-by":"publisher","first-page":"1436217","DOI":"10.3389\/fendo.2024.1436217.Frontiers+1PMC+1","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Wang Y, Zhang Y, et al. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials. Front Endocrinol (Lausanne). 2024;15:1436217. https:\/\/doi.org\/10.3389\/fendo.2024.1436217.Frontiers+1PMC+1.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"832_CR63","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3389\/fneur.2021.00748","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim S, Lee Y, Lee J, et al. Neuroprotective effect of SGLT2 inhibitors. Front Neurol. 2021;12:748. https:\/\/doi.org\/10.3389\/fneur.2021.00748.","journal-title":"Front Neurol"},{"issue":"8","key":"832_CR64","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/20406223221086996","volume":"47","author":"IK Wium-Andersen","year":"2022","unstructured":"Wium-Andersen IK, Wium-Andersen MK, J\u00f8rgensen MB, et al. Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. J Clin Pharm Ther. 2022;47(8):1255\u201364. https:\/\/doi.org\/10.1177\/20406223221086996.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"832_CR65","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056925","volume":"12","author":"SC Palmer","year":"2022","unstructured":"Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and cognitive outcomes: a systematic review and meta-analysis. BMJ Open. 2022;12(6):e059786.","journal-title":"BMJ Open"},{"issue":"9","key":"832_CR66","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-020-0072-x","volume":"19","author":"SC Cunnane","year":"2020","unstructured":"Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609\u201333.","journal-title":"Nat Rev Drug Discov"},{"key":"832_CR67","volume":"177","author":"M Nasiri","year":"2022","unstructured":"Nasiri M, Fatahi S, Azimi A, et al. Anti-inflammatory and antioxidant effects of SGLT2 inhibitors: new insights into their mechanisms of action. Pharmacol Res. 2022;177:106115.","journal-title":"Pharmacol Res"},{"issue":"6","key":"832_CR68","first-page":"571","volume":"143","author":"S Verma","year":"2021","unstructured":"Verma S, McMurray JJV. The serendipitous story of SGLT2 inhibitors in heart failure: new insights into mechanisms of benefit. Circulation. 2021;143(6):571\u20133.","journal-title":"Circulation"},{"issue":"12","key":"832_CR69","volume":"1866","author":"P Sa-Nguanmoo","year":"2020","unstructured":"Sa-Nguanmoo P, Tanajak P, Kerdphoo S, et al. SGLT2 inhibition by dapagliflozin improves brain insulin sensitivity, reduces beta-amyloid and tau pathology, and prevents cognitive decline in obese-insulin-resistant rats. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165937.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"832_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12179","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1):e12179.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"832_CR71","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jama.2019.10551","volume":"322","author":"IM Nasrallah","year":"2019","unstructured":"Nasrallah IM, Pajewski NM, Auchus AP, et al. Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA. 2019;322(6):524\u201334.","journal-title":"JAMA"},{"key":"832_CR72","doi-asserted-by":"publisher","first-page":"668614","DOI":"10.3389\/fnagi.2021.668614","volume":"13","author":"A Dunalska","year":"2021","unstructured":"Dunalska A, Pikul J, Schok K, Wiejak KA, Alster P. The significance of vascular pathogenesis in the examination of corticobasal syndrome. Front Aging Neurosci. 2021;13:668614. https:\/\/doi.org\/10.3389\/fnagi.2021.668614.","journal-title":"Front Aging Neurosci"},{"key":"832_CR73","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.parkreldis.2019.07.036","volume":"66","author":"D Standaert","year":"2019","unstructured":"Standaert D, Sudarsky L, et al. Hypertension and progressive supranuclear palsy. Parkinson Related Disorders. 2019;66:166\u201370.","journal-title":"Parkinson Related Disorders"},{"issue":"5","key":"832_CR74","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/jnnp-2020-324144","volume":"92","author":"I Sibon","year":"2021","unstructured":"Sibon I, et al. Environmental risk factors for progressive supranuclear palsy. J Neurol Neurosurg Psychiat. 2021;92(5):541\u20137. https:\/\/doi.org\/10.1136\/jnnp-2020-324144.","journal-title":"J Neurol Neurosurg Psychiat"},{"issue":"9","key":"832_CR75","first-page":"487","volume":"37","author":"Y Su","year":"2014","unstructured":"Su Y, et al. Insulin resistance and its role in neurodegenerative diseases. Trends Neurosci. 2014;37(9):487\u201393.","journal-title":"Trends Neurosci"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00832-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00832-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:04:18Z","timestamp":1763381058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00832-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00832-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paulina Kostrzewska, Pawel Kuca, Przemys\u0142aw Witek, Jolanta Ma\u0142yszko, Natalia Madetko-Alster, and Piotr Alster declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}